Wolfe Research downgraded AbbVie from Outperform to Peer Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/25/2026 | $260.00 | Outperform | RBC Capital Mkts |
| 2/20/2026 | $275.00 | Overweight | Barclays |
| 1/8/2026 | Outperform → Peer Perform | Wolfe Research | |
| 1/7/2026 | $240.00 | Neutral | UBS |
| 12/10/2025 | $265.00 | Hold → Buy | HSBC Securities |
| 11/13/2025 | $280.00 | Sector Outperform | Scotiabank |
| 11/4/2025 | $237.00 | Buy → Hold | DZ Bank |
| 10/14/2025 | Buy → Hold | Erste Group |
SCHEDULE 13G/A - AbbVie Inc. (0001551152) (Subject)
DEFA14A - AbbVie Inc. (0001551152) (Filer)
DEF 14A - AbbVie Inc. (0001551152) (Filer)
Data highlights efficacy and safety of risankizumab in psoriatic disease, including high impact areas in psoriasis and long-term treatment of psoriatic arthritisData includes real-world evidence of minimal disease activity and clinical long-term safety outcomes of upadacitinib in atopic dermatitis, as well as investigational Phase 3 data for vitiligo and alopecia areata NORTH CHICAGO, Ill., March 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, March 27–31 in Denver, Colorado. AbbVie will present 24 abstracts at AAD, including one late-breaking presentati
- Five scientific e-posters highlight investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid improvement in glabellar lines (as early as 8 hours), robust and consistent efficacy, and a favorable safety profile across global patient populations- Real-world and clinical data reinforce onabotulinumtoxinA (BOTOX® Cosmetic) as a foundation for high patient satisfaction, natural-looking results, and the gateway to multimodal facial aesthetic treatment plans- Portfolio-wide results demonstrate continued investment in innovative, integrated approaches for patients and practitioners NORTH CHICAGO, Ill., March 26, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, w
Research reveals an industry mindset shift towards 'undetectable†' aesthetics, as people seek a natural-looking, personalized approach and a subtle, rejuvenated appearance that is almost imperceptible1,2,‡Leading healthcare professionals discussed the findings at an Allergan Aesthetics* event at AMWC, which reaffirm 'undetectable' aesthetics, and the positive role of HA injectables in helping to achieve a discreet 'look'1,2,§The latest findings are part of Allergan Aesthetics' ongoing commitment to quality education and helping shape the future of HA injectablesTogether with trusted healthcare practitioners, the JUVÉDERM® Collection of Fillers is committed to advancing a new era of HA inject
4/A - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
4 - AbbVie Inc. (0001551152) (Issuer)
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination
Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form
Submission status for ABBVIE INC's drug SKYRIZI (SUPPL-7) with active ingredient RISANKIZUMAB-RZAA has changed to 'Approval' on 06/18/2024. Application Category: BLA, Application Number: 761262, Application Classification:
RBC Capital Mkts initiated coverage of AbbVie with a rating of Outperform and set a new price target of $260.00
Barclays initiated coverage of AbbVie with a rating of Overweight and set a new price target of $275.00
Wolfe Research downgraded AbbVie from Outperform to Peer Perform
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025NORTH CHICAGO, Ill., Feb. 14, 2025 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that its board of directors has unanimously elected chief executive officer (CEO) Robert A. Michael to assume the additional position of chairman, effective July 1, 2025. He will succeed Richard A. Gonzalez, who formerly served as AbbVie's CEO and has been chairman since the Company's formation in 2013. "I want to extend my heartfelt gratitude to Rick for his remarkable leadership and dedicated service," said Roxanne S. Austin, lead independent director. "The board and I have complete confidence in Rob, and we are fortunate to
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share. The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of
Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per Share Related to 2025 Acquired IPR&D and Milestones Expense Delivers Full-Year Net Revenues of $61.160 Billion, an Increase of 8.6 Percent on a Reported Basis and 8.5 Percent on an Operational Basis Full-Year Global Net Revenues from the Immunology Portfolio Were $30.406 Billion, an Increase of 14.0 Percent on a Reported Basis, or 13.9 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $17.562 Billion; Global Rinvoq Net Revenues Were $8.304 Billion; Global Humira Net Revenues Wer
NORTH CHICAGO, Ill., Jan. 7, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its full-year and fourth-quarter 2025 financial results on Wednesday, February 4, 2026, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key t
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)
SC 13G/A - AbbVie Inc. (0001551152) (Subject)